A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD6008 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations (TIAN-SHAN1)
This study is testing a new medication called DZD6008, along with another treatment called sunvozertinib, for people with advanced lung cancer. Researchers want to see how safe these medications are and how well they work against tumors with specific genetic mutations.
You might be able to join if you are 18 or older and have advanced non-small cell lung cancer with specific EGFR gene mutations that have not responded to standard treatments. You will also need to provide a tumor tissue sample and meet other health guidelines.
Participants will receive the study medications and be closely monitored by the medical team to check for safety, side effects, and how the body handles the treatment. This involves regular check-ups and providing tissue samples.
The study is currently actively recruiting participants at locations in New York, New York, and Fairfax, Virginia. Your care team can help you find the most convenient location.
- 1Tests new targeted medications for advanced lung cancer
- 2Requires specific EGFR gene mutations in your tumor
- 3Currently recruiting patients at select US locations
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.